汉防己甲素治疗尘肺的系统评价

发布时间：2018-03-07 18:04

本文选题：尘肺　切入点：矽肺　出处：《临床医药实践》2016年08期 　论文类型：期刊论文

【摘要】：目的:评价汉防己甲素治疗尘肺(矽肺)的临床疗效。方法:在Pub Med,EMBASE,CENTRAL,CBM,CNKI及VIP和万方等数据库中检索2000年1月—2015年5月关于汉防己甲素治疗尘肺的临床对照试验,然后对其进行筛选和质量评价,并对符合标准的文献进行Meta分析。结果:纳入17项研究,共1 194例尘肺患者,汉防己甲素治疗组临床疗效有效率、部分肺功能[一秒呼气容积(FEV1),残气量/肺总量(RV/TLC)]、部分免疫细胞表达(CD4,CD8,CD4/CD8)与对照组对比,差异有统计学意义(P0.05)。但在免疫细胞表达CD3、临床症状积分(咳嗽、咳痰、胸痛、呼吸困难)、肺功能[用力肺活量(FVC)、一秒呼气容积/用力肺活量(FEV1/FVC)、肺活量(VC)]方面汉防己甲素治疗组与对照组相比有改善的趋势,但差异无统计学意义(P0.05)。结论:与对照组相比,汉防己甲素可以在一定程度上提高尘肺治疗的临床疗效、部分免疫功能及肺功能。但在改善临床症状方面效果不显著,仍需开展更多高质量的多中心、大样本、前瞻性、随机、双盲临床试验加以验证。
[Abstract]:Objective: to evaluate the clinical efficacy of Tetrandrine in the treatment of pneumoconiosis (silicosis). Methods: a controlled clinical trial of Tetrandrine in the treatment of pneumoconiosis from January 2000 to May 2015 was conducted in the databases of Pub Medmella, VIP and Wanfang. Then screening and quality evaluation were carried out, and Meta analysis was carried out on the literature that met the standard. Results: in 17 studies, 1 194 patients with pneumoconiosis were treated with Tetrandrine (Tetrandrine). Part of lung function [1 second expiratory volume of FEV1, residual volume / total lung volume of RV / TLC], partial immunocyte expression of CD4 + CD8 / CD8 / CD8) compared with control group, there were significant differences in the expression of CD3, clinical symptom score (cough, expectoration, chest pain) between the two groups (P 0.05), but the expression of CD3 in immune cells was significantly higher than that in control group (P < 0.05). In terms of dyspnea, pulmonary function [forced vital capacity / forced vital capacity / FEV 1 / FVC], Tetrandrine treatment group showed an improved trend compared with control group, but the difference was not statistically significant (P 0.05). Conclusion: compared with control group, Tetrandrine treatment group has a tendency to improve. Tetrandrine can improve the clinical efficacy, immune function and lung function of pneumoconiosis to a certain extent. However, the effect of Tetrandrine on improving clinical symptoms is not significant. Double blind clinical trials were performed.
【作者单位】：赣州市第五人民医院;
【分类号】：R135.2

【相似文献】